Update on optimal use of omalizumab in management of asthma
Girolamo Pelaia1, Luca Gallelli1, Teresa Renda1, Pasquale Romeo1, Maria Teresa Busceti1, Rosa Daniela Grembiale1, Rosario Maselli1, Serafino Antonio Marsico2, Alessandro Vatrella31Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro; 2Depart...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-06-01
|
| Series: | Journal of Asthma and Allergy |
| Online Access: | http://www.dovepress.com/update-on-optimal-use-of-omalizumab-in-management-of-asthma-a7637 |
| _version_ | 1817994312088027136 |
|---|---|
| author | Pelaia G Gallelli L Renda T Romeo P Busceti MT Grembiale RD Maselli R Marsico SA Vatrella A |
| author_facet | Pelaia G Gallelli L Renda T Romeo P Busceti MT Grembiale RD Maselli R Marsico SA Vatrella A |
| author_sort | Pelaia G |
| collection | DOAJ |
| description | Girolamo Pelaia1, Luca Gallelli1, Teresa Renda1, Pasquale Romeo1, Maria Teresa Busceti1, Rosa Daniela Grembiale1, Rosario Maselli1, Serafino Antonio Marsico2, Alessandro Vatrella31Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro; 2Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Naples; 3Department of Respiratory Medicine, University of Salerno, Salerno, ItalyAbstract: Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.Keywords: omalizumab, anti-IgE, severe asthma |
| first_indexed | 2024-04-14T01:51:15Z |
| format | Article |
| id | doaj.art-15b61a7d85b6480b874d097a1e88c4cf |
| institution | Directory Open Access Journal |
| issn | 1178-6965 |
| language | English |
| last_indexed | 2024-04-14T01:51:15Z |
| publishDate | 2011-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Asthma and Allergy |
| spelling | doaj.art-15b61a7d85b6480b874d097a1e88c4cf2022-12-22T02:19:20ZengDove Medical PressJournal of Asthma and Allergy1178-69652011-06-012011default4959Update on optimal use of omalizumab in management of asthmaPelaia GGallelli LRenda TRomeo PBusceti MTGrembiale RDMaselli RMarsico SAVatrella AGirolamo Pelaia1, Luca Gallelli1, Teresa Renda1, Pasquale Romeo1, Maria Teresa Busceti1, Rosa Daniela Grembiale1, Rosario Maselli1, Serafino Antonio Marsico2, Alessandro Vatrella31Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro; 2Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Naples; 3Department of Respiratory Medicine, University of Salerno, Salerno, ItalyAbstract: Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.Keywords: omalizumab, anti-IgE, severe asthmahttp://www.dovepress.com/update-on-optimal-use-of-omalizumab-in-management-of-asthma-a7637 |
| spellingShingle | Pelaia G Gallelli L Renda T Romeo P Busceti MT Grembiale RD Maselli R Marsico SA Vatrella A Update on optimal use of omalizumab in management of asthma Journal of Asthma and Allergy |
| title | Update on optimal use of omalizumab in management of asthma |
| title_full | Update on optimal use of omalizumab in management of asthma |
| title_fullStr | Update on optimal use of omalizumab in management of asthma |
| title_full_unstemmed | Update on optimal use of omalizumab in management of asthma |
| title_short | Update on optimal use of omalizumab in management of asthma |
| title_sort | update on optimal use of omalizumab in management of asthma |
| url | http://www.dovepress.com/update-on-optimal-use-of-omalizumab-in-management-of-asthma-a7637 |
| work_keys_str_mv | AT pelaiag updateonoptimaluseofomalizumabinmanagementofasthma AT gallellil updateonoptimaluseofomalizumabinmanagementofasthma AT rendat updateonoptimaluseofomalizumabinmanagementofasthma AT romeop updateonoptimaluseofomalizumabinmanagementofasthma AT buscetimt updateonoptimaluseofomalizumabinmanagementofasthma AT grembialerd updateonoptimaluseofomalizumabinmanagementofasthma AT masellir updateonoptimaluseofomalizumabinmanagementofasthma AT marsicosa updateonoptimaluseofomalizumabinmanagementofasthma AT vatrellaa updateonoptimaluseofomalizumabinmanagementofasthma |